A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Latest Information Update: 28 Oct 2022
At a glance
- Drugs PSC 100 (Primary)
- Indications Acute myeloid leukaemia; Adrenoleucodystrophy; Anaemia; Gaucher's disease; Globoid cell leukodystrophy; Metachromatic leukodystrophy; Mucopolysaccharidosis I; Mucopolysaccharidosis VI; Myelodysplastic syndromes; Neuronal ceroid lipofuscinosis; Niemann-Pick diseases; Precursor cell lymphoblastic leukaemia-lymphoma; Thrombocytopenia; Wolman disease
- Focus Adverse reactions
- Acronyms HPDSC
- 24 Oct 2022 Status changed from active, no longer recruiting to completed.
- 29 Oct 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 26 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.